International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis
NCT06393543 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2024-05-01
Summary
To prospectively assess the incidence of peritoneal carcinomatosis for women with isolated STIC (serous tubal intraepithelial carcinoma). Moreover, to identify histopathological characteristics of STIC which are reproducible and associated to the risk of peritoneal carcinomatosis and to report the findings of additional diagnostics.
Conditions
- BRCA Mutation
- Serous Tubal Intraepithelial Carcinoma
- Ovarian Carcinoma
- Peritoneal Carcinoma
Interventions
- OTHER
-
No intervention, only registration
No intervention, only registration
Sponsors & Collaborators
-
Radboud University Medical Center
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-30
- Primary Completion
- 2034-06-30
- Completion
- 2034-06-30
More Related Trials
-
Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
NCT00349505 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis
NCT00352755 ·Status: TERMINATED ·Phase: PHASE2
-
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01767675 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052 ·Status: RECRUITING ·Phase: NA
-
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01853644 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT05903833 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT01381861 ·Status: COMPLETED ·Phase: PHASE2
-
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)
NCT03931304 ·Status: COMPLETED
-
Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma
NCT03959761 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
NCT00189345 ·Status: COMPLETED ·Phase: PHASE2
-
Sub-type Specific Genomic Mutations in sBOTs
NCT03883542 ·Status: ACTIVE_NOT_RECRUITING
-
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472 ·Status: COMPLETED
-
Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients
NCT01905163 ·Status: COMPLETED ·Phase: PHASE2
-
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer
NCT02567253 ·Status: COMPLETED ·Phase: PHASE2
-
Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers
NCT05186493 ·Status: RECRUITING ·Phase: NA
-
Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer
NCT06535334 ·Status: NOT_YET_RECRUITING
-
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00055614 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
NCT01697488 ·Status: COMPLETED
-
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01074411 ·Status: COMPLETED ·Phase: PHASE1
-
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01932125 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
NCT06312124 ·Status: RECRUITING ·Phase: NA
-
Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer
NCT00949039 ·Status: COMPLETED ·Phase: PHASE3
-
Immunologic Profile of Peritoneal Cancer
NCT03230240 ·Status: UNKNOWN
-
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04683653 ·Status: RECRUITING ·Phase: PHASE1/PHASE2